Prevention of drug-induced memory impairment by immunopharmacotherapy

Journal of Medicinal Chemistry

Volumn 51, Issue 21, 2008, Pages 6866-6875

  Treweek, Jennifer B ^a   Sun, Chengzao ^a   Mayorov, Alexander V ^a   Qi, Longwu ^a   Levy, Coree L ^a   Roberts, Amanda J ^a   Dickerson, Tobin J ^a   Janda, Kim D ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; COCAINE MONOCLONAL ANTIBODY GNC92H2; DRUG ANTIBODY; FLUNITRAZEPAM; FLUNITRAZEPAM MONOCLONAL ANTIBODY RCA3A3; HAPTEN; UNCLASSIFIED DRUG;

AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COGNITION; CONTROLLED STUDY; DRUG EFFECT; DRUG INTOXICATION; DRUG MISUSE; DRUG STRUCTURE; FEAR; FEMALE; IMMUNOPHARMACOLOGY; INSTRUMENTAL CONDITIONING; MEMORY CONSOLIDATION; MEMORY DISORDER; MOTOR PERFORMANCE; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; SEDATION; TREATMENT OUTCOME; VACCINATION;

ANIMALS; ANTIBODIES, MONOCLONAL; FEMALE; FLUNITRAZEPAM; IMMUNOTHERAPY; LOCOMOTION; MEMORY DISORDERS; MICE; MOLECULAR STRUCTURE;

EID: 56249090050     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm800506v     Document Type: Article

References (44)

1. Meijler, M. M.; Matsushita, M.; Wirsching, P.; Janda, K. D. Development of immunopharmacotherapy against drugs of abuse. Curr. Drug Discovery Technol. 2004, 1 (1), 77-89.
2. Kosten, T.; Owens, S. M. Immunotherapy for the treatment of drug abuse. Pharmacol. Ther. 2005, 108 (1), 76-85.
3. Pentel, P. R.; Dufek, M. B.; Roiko, S. A.; Lesage, M. G.; Keyler, D. E. Differential effects of passive immunization with nicotine-specific antibodies on the acute and chronic distribution of nicotine to brain in rats. J. Pharmacol. Exp. Ther. 2006, 317 (2), 660-666.
4. Utzinger, R. Hapten-immunological studies on mescaline. Psychopharmacologia 1975, 41 (3), 301-304.
5. Fox, B. S.; Kantak, K. M.; Edwards, M. A.; Black, K. M.; Bollinger, B. K.; Botka, A. J.; French, T. L.; Thompson, T. L.; Schad, V. C.; Greenstein, J. L.; Gefter, M. L.; Exley, M. A.; Swain, P. A.; Briner, T. J. Efficacy of a therapeutic cocaine vaccine in rodent models. Nat. Med. 1996, 2, 1129-1132.
6. Valentine, J. L.; Mayersohn, M.; Wessinger, W. D.; Arnold, L. W.; Owens, S. M. Antiphencyclidine monoclonal Fab fragments reverse phencyclidine-induced behavioral effects and ataxia in rats. J. Pharmacol. Exp. Ther. 1996, 278 (2), 709-716.
7. Kantak, K. M.; Collins, S. L.; Lipman, E. G.; Bond, J.; Giovanoni, K.; Fox, B. S. Evaluation of anti-cocaine antibodies and a cocaine vaccine in a rat self-administration model. Psychopharmacology 2000, 148 (3), 251-262.
8. Hardin, J. S.; Wessinger, W. D.; Wenger, G. R.; Proksch, J. W.; Laurenzana, E., M.; Owens, S. M. A single dose of monoclonal anti-phencyclidine IgG offers long-term reductions in phencyclidine behavioral effects in rats. J. Pharmacol. Exp. Ther. 2002, 302, 119-126.
9. Gentry, W. B.; Laurenzana, E. M.; Williams, D. K.; West, J. R.; Berg, R. J.; Terlea, T.; Owens, S. M. Safety and efficiency of an anti-(+)- methamphetamine monoclonal antibody in the protection against cardiovascular and central nervous system effects of (+)-methamphetamine in rats. Int. Immunopharmacol. 2006, 6, 968-977.
10. Carrera, M. R. A.; Trigo, J. M.; Wirshing, P.; Roberts, A. J.; Janda, K. D. Evaluation of the anticocaine monoclonal antibody GNC92H2 as an immunotherapy for cocaine overdose. Pharmacol., Biochem. Behav. 2005, 81, 709-714.
11. Malin, D. H.; Lake, J. R.; Lin, A.; Saldana, M.; Balch, L.; Irvin, M. L. L.; Chandrasekara, H.; Alvarado, C. L.; Hieda, Y.; Keyler, D. E. Passive immunization against nicotine prevents nicotine alleviation of nicotine abstinence syndrome. Pharmacol., Biochem. Behav. 2001, 68 (1), 87-92.
12. Mattila, M. A. K.; Larni, H. M. Flunitrazepam: a review of its pharmacological properties and therapeutic use. Drugs 1980, 20 (5), 353-374.
13. Berezhnoy, D.; Nyfeler, Y.; Gonthier, A.; Schwob, H.; Goeldner, M.; Sigel, E. On the benzodiazepine binding pocket in GABAA receptors. J. Biol. Chem. 2004, 279 (5), 3160-3168.
14. Drummer, O. H.; Syrjanen, M. L.; Cordner, S. M. Deaths involving the benzodiazepine flunitrazepam. Am. J. Forensic Med. Pathol. 1993, 14 (3), 238-243.
15. Farre, M.; Teran, M.-T.; Roset, P. N.; Mas, M.; Torrens, M.; Cami, J. Abuse liability of flunitrazepam among methadone-maintained patients. Psychopharmacology 1998, 140, 486-495.
16. Gambi, F.; Conti, C. M.; Grimaldi, M. R.; Giampietro, L.; De Bernardis, B.; Ferro, F. M. Flunitrazepam a benzodiazepine most used among drug abusers. Int. J. Immunopathol. Pharmacol. 1999, 12 (3), 157-159.
17. Mintzer, M. Z.; Griffiths, R. R. An abuse liability comparison of flunitrazepam and triazolam in sedative drug abusers. Behav. Pharmacol. 2005, 16 (7), 579-584.
18. Schwartz, R. H.; Weaver, A. B. Rohypnol, the date rape drug. Clin. Pediatr. 1998, 37, 321.
19. Smith, K. M. Drugs used in acquaintance rape. J. Am. Pharm. Assoc. 1999, 39, 519-583.
20. DEA Congressional Testimony, House Commerce Committee Subcommittee on Oversight and Investigations, 106th Congress, 1st Session; U.S. Drug Enforcement Administration: Springfield, VA, 1999.
21. Frye, S. V.; Johnson, M. C.; Valvano, N. L. Synthesis of 2-aminobenzophenones via rapid halogen-lithium exchange in the presence of a 2-amino-N-methoxy-N-methylbenzamide. J. Org. Chem. 1991, 56, 3750-3752.
22. Carpino, L. A. 1-Hydroxy-7-azabenzotriazole. An efficient peptide coupling additive. J. Am. Chem. Soc. 1993, 115, 4397-4398.
23. Sternbach, L. H.; Fryer, R. I.; Metlesics, W.; Sach, G.; Stempel, A. Quinazolines and 1,4-benzodiazepines. V. o-Aminobenzophenones. J. Org. Chem. 1962, 27 (11), 3781-3788.
24. Sternbach, L. H.; Fryer, R. I.; Keller, O.; Metlesics, W.; Sach, G.; Steiger, N. Quinazolinesand 1,4-benzodiazepines. X. Nitro-substituted 5-phenyl-1,4-benzodiazepine derivatives. J. Med. Chem. 1963, 6, 261-265.
25. Carrera, M. R. A.; Ashley, J. A.; Parsons, L. H.; Wirshing, P.; Koob, G. F.; Janda, K. D. Suppression of psychoactive effects of cocaine by active immunization. Nature 1995, 378 (6558), 727-730.
26. Carrera, M. R. A.; Ashley, J. A.; Zhou, B.; Wirsching, P.; Koob, G. F.; Janda, K. D. Cocaine vaccines: antibody protection against relapse in a rat model. Proc. Natl. Acad. Sci. U.S.A. 2000, 97 (11), 6202-6206.
27. Deroche, V.; Caine, S. B.; Heyser, C. J.; Polis, I.; Koob, G. F.; Gold, L. H. Differences in the liability to self-administer intravenous cocaine between C57BL/6 x SJL and BALB/cByJ mice. Pharmacol., Biochem. Behav. 1997, 57 (3), 429-440.
28. Isomura, S.; Wirsching, P.; Janda, K. D. An immunotherapeutic program for the treatment of nicotine addiction: hapten design and synthesis. J. Org. Chem. 2001, 66 (12), 4115-4121.
29. Matsushita, M.; Hoffman, T. Z.; Ashley, J. A.; Zhou, B.; Wirsching, P.; Janda, K. D. Cocaine catalytic antibodies: the primary importance of linker effects. Bioorg. Med. Chem. Lett. 2001, 11 (2), 87-90.
30. Meijler, M. M.; Matsushita, M.; Altobell, L. J., III.; Wirsching, P.; Janda, K. D. A new strategy for improved nicotine vaccines using conformationally constrained haptens. J. Am. Chem. Soc. 2003, 125 (47), 164-165.
31. Ino, A.; Dickerson, T. J.; Janda, K. D. Positional linker effects in haptens for cocaine immunopharmacotherapy. Bioorg. Med. Chem. Lett. 2007, 17 (15), 4280-4283.
32. Qi, L.; Yamamoto, N.; Meijler, M. M.; Altobell, L. J.; Koob, G. F.; Wirsching, P.; Janda, K. D. Delta-9-tetrahydrocannabinol immunochemical studies: haptens, monoclonal antibodies, and a convenient synthesis of radiolabeled delta-9-tetrahydrocannabinol. J. Med. Chem. 2005, 48 (23), 7389-7399.
33. Fryer, R. I.; Gu, Z. Q. The rational design and synthesis of haptens having specific activity as full agonists or full antagonists at the benzodiazepine receptor. Life Sci. 1990, 47 (10), 833-840.
34. Peterson, E. C.; Gunnell, M.; Che, Y.; Goforth, R. L.; Carroll, F. I.; Henry, R.; Liu, H.; Owens, S. M. Using hapten design to discover therapeutic monoclonal antibodies for treating methamphetamine abuse. J. Pharmacol. Exp. Ther. 2007, 322 (1), 30-39.
35. Castellano, C.; Pavone, F. Effects of flunitrazepam on passive avoidance behaviour in mice subjected to immobilization stress or familiarized with the testing apparatus. Behav. Brain Res. 1986, 22 (1), 91-95.
36. Bowers, B. J.; Elliott, K. J.; Wehner, J. M. Differential sensitivity to the anxiolytic effects of ethanol and flunitrazepam in PKCgamma null mutant mice. Pharmacol., Biochem. Behav. 2001, 69, 99-110.
37. Savić, M. M.; Obradović, D. I.; Ugresić, N. D.; Cook, J. M.; Yin, W.; Van Linn, M.; Bokonjić, D. R. Benzodiazepine site inverse agonists and locomotor activity in rats: bimodal and biphasic influence. Pharmacol., Biochem. Behav. 2006, 84 (1), 35-42.
38. DeLorey, T. M.; Lin, R. C.; McBrady, B.; He, X.; Cook, J. M.; Lameh, J.; Loew, G. H. Influence of benzodiazepine binding site ligands on fear-conditioned contextual memory. Eur. J. Pharmacol. 2001, 426 (1-2), 45-54.
39. Blanchard, D. C.; Griebel, G.; Blanchard, R. J. The mouse defense test battery: pharmacological and behavioral assays for anxiety and panic. Eur. J. Pharmacol. 2003, 463 (1-3), 97-116.
40. Guscott, M. R.; Cook, G. P.; Bristow, L. J. Contextual fear conditioning and baseline startle responses in the rat fear-potentiated startle test: a comparison of benzodiazepine/gamma-aminobutyric acid-A receptor agonists. Behav. Pharmacol. 2000, 11 (6), 495-504.
41. Brignell, C. M.; Curran, H. V. Drugs, sweat, and fears: a comparison of the effects of diazepam and methylphenidate on fear conditioning. Psychopharmacology 2006, 186 (4), 504-516.
42. Fendt, M.; Fanselow, M. S. The neuroanatomical and neurochemical basis of conditioned fear. Neurosci. Behav. Rev. 1999, 23 (5), 743-760.
43. Harris, J. A.; Westbrook, R. F. Contextual control over the expression of fear in rats conditioned under a benzodiazepine. Psychopharmacology 2001, 156, 92-97.
44. Harris, J. A.; Westbrook, R. F. The benzodiazepine midazolam does not impair Pavlovian fear conditioning but regulates when and where that fear is expressed. J. Exp. Psychol. Anim. Behav. Process 1999, 25, 236-246.